Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial
Circulation · 21.10.2025 · 152 (16) · 1136-1145
DOI: 10.1161/circulationaha.125.076616 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 21.10.2025. Verfasst von Torbjørn Omland und 12 weiteren Autor:innen. Beteiligte Einrichtung: K.G. Jebsen Centre for Cardiac Biomarkers, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway (T.O., S.L.H., M.N.G…. Hauptthemen laut MEDLINE: Aminobutyrates, Angiotensin Receptor Antagonists, Breast Neoplasms, Heart Diseases. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Programme for Clinical Therapy Research in the Specialist Health Service, Norwegian Cancer Society, Kristian.Gerhard Jebsen Foundation.
Abstract (Originalsprache)
BACKGROUND: Anthracycline- and trastuzumab-associated cardiotoxicity may lead to cardiac dysfunction and dose reduction or halt of potentially life-saving adjuvant cancer therapy. Whether angiotensin receptor/neprilysin inhibitors can prevent cancer therapy–related cardiac dysfunction and injury remains to be established. METHODS: PRADA II (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) was a randomized, parallel-group, placebo-controlled, double-blind, multicenter trial conducted at 4 academic medical centers in Norway that evaluated the cardioprotective effect of sacubitril/valsartan versus placebo administered concomitantly with anthracycline-containing breast cancer therapy and continued for 18 months. The target dose was 97/103 mg BID. The primary outcome was change in left ventricular ejection fraction by cardiovascular magnetic resonance from prior to initiation of chemotherapy to 18 months thereafter. Secondary outcomes included change in echocardiographic global longitudinal strain, circulating cardiac troponins, and NT-proBNP (N-terminal pro-B-type natriuretic peptide). RESULTS: In total, 138 women (mean±SD age: 54.0±9.4 years) were randomized. The overall decline in left ventricular ejection fraction from baseline to 18 months was 2.2 percentage points (95% CI, 1.1 to 3.3) in the placebo group and 1.1 percentage points (95% CI, −0.01 to 2.2) in the sacubitril/valsartan group. The between-group difference was 1.1 percentage points (95% CI, −0.4 to 2.7; P =0.16). Left ventricular global longitudinal strain was normal and remained stable in the sacubitril/valsartan group throughout the study (change from baseline to 18 months, −0.3 [95% CI, −0.80 to 0.2]). In contrast, there was a progressive decline in the placebo group (change from baseline to 18 months, 0.5 [95% CI, 0.05 to 1.0]). The between-group difference was −0.9 (95% CI, −1.5 to −0.2). The mean increases in NT-proBNP and cardiac troponin I concentrations from baseline to 18 months were greater in the placebo group than in the sacubitril/valsartan group (log difference, 0.3 [95% CI, 0.05 to 0.6] for NT-proBNP and 0.5 [95% CI, 0.1to 1.0] for cardiac troponin I). CONCLUSIONS: Anthracycline-based treatment for early breast cancer was associated with a reduction in left ventricular ejection fraction that was not significantly attenuated by sacubitril/valsartan. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03760588.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- K.G. Jebsen Centre for Cardiac Biomarkers, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway (T.O., S.L.H., M.N.G., V.V.-J., G.G.).
- Departments of Cardiology (T.O., A.M.L., V.V.-J.), Akershus University Hospital, Lørenskog, Norway.
- Diagnostic Imaging (S.L.H.), Akershus University Hospital, Lørenskog, Norway.
- Departments of Circulation and Medical Imaging (E.H.), NTNU-Norwegian University of Science and Technology, Trondheim, Norway.
- Clinics of Cardiology (E.H., M.N.G.), St. Olavs Hospital, Trondheim, Norway.
- Oslo Center for Biostatistics and Epidemiology, Research Support Services (M.W.F.), Oslo University Hospital, Norway.
ORCID-Profile: Torbjørn Omland, Siri Lagethon Heck, Mari Nordbø Gynnild, Morten Wang Fagerland, Alf Inge Larsen, Jürgen Geisler, Geeta Gulati
Förderung
- National Programme for Clinical Therapy Research in the Specialist Health Service
- Norwegian Cancer Society
- Kristian.Gerhard Jebsen Foundation
Zitieren
APA
Omland, T., Heck, S. L., Holte, E., Lilleaasen, A. M., Gynnild, M. N., Fagerland, M. W., Vinje-Jakobsen, V., Næs, A. L., Blix, E. S., Larsen, A. I., Geisler, J., Gulati, G., & Wethal, T. (2025). Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Circulation, 152(16), 1136-1145. https://doi.org/10.1161/circulationaha.125.076616
Vancouver
Omland T, Heck SL, Holte E, Lilleaasen AM, Gynnild MN, Fagerland MW, et al. Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Circulation. 2025;152(16):1136-1145. doi:10.1161/circulationaha.125.076616
BibTeX
@article{Omland2025,
author = {Omland, Torbjørn and Heck, Siri Lagethon and Holte, Espen and Lilleaasen, Albulena Mecinaj and Gynnild, Mari Nordbø and Fagerland, Morten Wang and Vinje-Jakobsen, Victoria and Næs, Anne-Katrine Lislegaard and Blix, Egil Støre and Larsen, Alf Inge and Geisler, Jürgen and Gulati, Geeta and Wethal, Torgeir},
title = {Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial},
journal = {Circulation},
year = {2025},
volume = {152},
number = {16},
pages = {1136--1145},
doi = {10.1161/circulationaha.125.076616}
}
EUVIMED